Differential Roles of Two N-Acetylgalactosaminyltransferases, CSGalNAcT-1, and a Novel Enzyme, CSGalNAcT-2

INITIATION AND ELONGATION IN SYNTHESIS OF CHONDROITIN SULFATE*

Takashi SatoDagger , Masanori GotohDagger §, Katsue KiyoharaDagger , Tomohiro AkashimaDagger , Hiroko IwasakiDagger §, Akihiko KameyamaDagger §, Hideo MochizukiDagger , Toshikazu Yada||, Niro InabaDagger **, Akira TogayachiDagger , Takashi KudoDagger Dagger Dagger , Masahiro Asada§§, Hideto Watanabe||, Toru Imamura§§, Koji Kimata||, and Hisashi NarimatsuDagger ¶¶

From the Dagger  Glycogene Function Team, Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Open Space Laboratory C-2, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan, § Amersham Biosciences KK, 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan, the  Seikagaku Corporation, 1253 Tateno 3-Chome, Higashi-yamato, Tokyo 207-0021, Japan, the || Institute for Molecular Science of Medicine, Aichi Medical University, Nagaute, Aichi 480-1195, Japan, ** JGS Japan Genome Solutions, Inc., 51 Kamiyacho, Hachioji, Tokyo 192-0031, Japan, the §§ Cell Regulation Team, Age Dimension Research Center, AIST, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan, the Dagger Dagger  New Energy and Industrial Technology Development Organization (NEDO), Sunshine 60 Bldg., 3-1-1 Higashi Ikebukuro, Toshima-ku Tokyo, 170-6028, Japan

Received for publication, August 30, 2002, and in revised form, November 19, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

By a tblastn search with beta 1,4-galactosyltransferases as query sequences, we found an expressed sequence tag that showed similarity in beta 1,4-glycosyltransferase motifs. The full-length complementary DNA was obtained by a method of 5'-rapid amplification of complementary DNA ends. The predicted open reading frame encodes a typical type II membrane protein comprising 543 amino acids, the sequence of which was highly homologous to chondroitin sulfate N-acetylgalactosaminyltransferase (CSGalNAcT-1), and we designated this novel enzyme CSGalNAcT-2. CSGalNAcT-2 showed much stronger N-acetylgalactosaminyltransferase activity toward glucuronic acid of chondroitin poly- and oligosaccharides, and chondroitin sulfate poly- and oligosaccharides with a beta 1-4 linkage, i.e. elongation activity for chondroitin and chondroitin sulfate, but showed much weaker activity toward a tetrasaccharide of the glycosaminoglycan linkage structure (GlcA-Gal-Gal-Xyl-O-methoxyphenyl), i.e. initiation activity, than CSGalNAcT-1. Transfection of the CSGalNAcT-1 gene into Chinese hamster ovary cells yielded a change of glycosaminoglycan composition, i.e. the replacement of heparan sulfate on a syndecan-4/fibroblast growth factor-1 chimera protein by chondroitin sulfate, however, transfection of the CSGalNAcT-2 gene did not. The above results indicated that CSGalNAcT-1 is involved in the initiation of chondroitin sulfate synthesis, whereas CSGalNAcT-2 participates mainly in the elongation, not initiation. Quantitative real-time PCR analysis revealed that CSGalNAcT-2 transcripts were highly expressed in the small intestine, leukocytes, and spleen, however, both CSGalNAcTs were ubiquitously expressed in various tissues.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteoglycans (PGs),1 molecules consisting of a core protein and at least one glycosaminoglycan (GAG) chain, exist as one of the major components of extracellular matrix and on the cell surface. A variety of proteoglycan functions are exerted depending on the GAG chains. These chains are usually highly sulfated, and can be classified into several groups including chondroitin sulfate (CS)/dermatan sulfate, heparan sulfate (HS)/heparin, and keratan sulfate based on the GAG composition. HS has been shown to be involved in signal transduction and development together with certain growth factors, cytokines, and extracellular matrices. In Drosophila melanogaster, HS deficiencies caused by mutations in the genes encoding enzymes involved in the synthesis of HS result in abnormal developmental phenotypes (1). HS has been demonstrated to bind to a variety of cell growth factors such as the fibroblast growth factor (FGF) family molecules and to modulate their activities in various ways (2). Hepatocyte growth factor (HGF) and some interleukins (interleukins 3 and 7) bind to HS for efficient signal transduction (3, 4). Recent studies have demonstrated that CS also plays various important roles in cell adhesion, migration, and recognition, especially of neuronal cells (5-7). The sulfation profiles of CS vary with aging in the cartilage (8, 9). Disulfated disaccharide units, CS-D (GlcA(2S)beta 1-3GalNAc(6S)) and CS-E (GlcAbeta 1-3GalNAc(4S,6S)), promote the outgrowth of neurites in rat brain (10). These reports suggest that HS and CS have different functions. Thus, it is of interest to clarify the mechanism for the biosynthesis of HS and CS, the molecules responsible for these diverse biological phenotypes.

The initial stage in the biosynthesis of both CS and HS involves a linkage tetrasaccharide structure (GlcAbeta 1-4Galbeta 1-3Galbeta 1-4Xylbeta 1-), which binds covalently to serine residues of core proteins. To initiate the synthesis of HS, a GlcNAc residue is transferred to GlcA of the linkage tetrasaccharide with an alpha 1-4 linkage. On the other hand, GalNAc is transferred to the same acceptor with a beta 1-4 linkage for the initiation of CS synthesis. Thus, because the acceptor substrate is identical, it is possible that the initiation enzyme for HS or CS synthesis compete with the acceptor substrate, i.e. the linkage tetrasaccharide bound to core proteins, in the cells. If this is the case, the initiation enzymes may play a key role in determining the species of the GAG chain, HS or CS, on the core proteins. After the initiation reaction, the addition of disaccharide units of GlcNAcalpha 1-4GlcAbeta 1-4 are repeated for elongation of the HS chain, whereas GalNAcbeta 1-4GlcAbeta 1-3 units are repeatedly added for polymerization of the CS chain.

For the synthesis of HS, five glycosyltransferase genes, EXT1, EXT2, EXTL1, EXTL2, and EXTL3, were cloned and their products characterized. They retain conserved motifs of short amino acid stretches in their COOH terminus and belong to one family. The EXT1 and EXT2 genes, which have been identified as tumor suppressor genes and were implicated in hereditary multiple exostoses, were found to encode HS polymerases having the activity of both beta 1,4-glucuronyltransferase (beta 4GlcAT) and alpha 1,4-N-acetylglucosaminyltransferase (alpha 4GlcNAcT) (11). Both enzymes are responsible for the elongation of HS chains. Three enzymes, EXTL1-3, exhibit only alpha 4GlcNAcT activity, but their substrate specificities were different. EXTL1 showed alpha 4GlcNAcT activity toward GlcA in elongation. EXTL2 showed activity in initiation. EXTL3 showed activity in both initiation and elongation for the synthesis of HS (12, 13).

Very recently, three glycosyltransferases, chondroitin synthase (CSS) (14), CS glucuronyltransferase (CSGlcAT) (15) and CSGalNAcT (16, 17), which are involved in the synthesis of CS, have been reported. CSS was found to be a CS polymerase having the activity of both beta 1,3-glucuronyltransferase (beta 3GlcAT) and beta 4GalNAcT. CSGlcAT or CSGalNAcT exhibits the activity of only one glycosyltransferase, beta 3GlcAT and beta 4GalNAcT, respectively. Furthermore, CSGalNAcT was found to exhibit apparent beta 4GalNAcT activity toward the linkage tetrasaccharide for the initiation of CS synthesis. Given the many enzymes involved in the synthesis of HS, it is easy to speculate that multiple glycosyltransferases would also participate in the synthesis of CS.

In this study, we report the cloning and characterization of a novel N-acetylgalactosaminyltransferase, CSGalNAcT-2, that is the fourth member participating in the synthesis of CS. In considering the substrate specificities of these two CSGalNAcTs in vitro, we suggest their differential roles in vivo.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Human CSGalNAcT-2 cDNA-- We performed a tblastn search of the GenBankTM data base using beta 1,4-glycosyltransferase motifs as queries and identified an expressed sequence tag with GenBankTM accession number NM_018590, which contained a partial open reading frame (ORF), but showed high homology to the carboxyl-terminal region of CSGalNAcT-1. An additional search of the Human Genome Project data base revealed that the genome sequence with GenBankTM accession number NT_008776 was identical to the expressed sequence tag. To obtain the complete ORF, the 5'-rapid amplification of complementary DNA (cDNA) ends method was employed using a Marathon ReadyTM cDNA Amplification Kit (Clontech, Palo Alto, CA). Two reverse primers were designed for the 1st PCR: GP245, 5'-GTCAGGAAATCTGAACGATGCTGA-3', and for the nested PCR, GP244, 5'-GCAGCTGTTAAGGAATTCGGCTGA-3'. The sequence of the DNA fragment obtained by the 5'-rapid amplification of complementary DNA method was determined using a DYEnamic ET Terminator Cycle Sequencing Kit (Amersham plc, Amersham Place, UK). Finally, a cDNA sequence encoding the ORF was obtained by PCR using the Marathon ReadyTM cDNA of human bone marrow tissue (Clontech) as a template.

Construction and Purification of CSGalNAcT Proteins Fused with FLAG Peptide-- The putative catalytic domain of CSGalNAcT-2 (amino acids 37 to 542) was expressed as a secreted protein fused with a FLAG peptide in insect cells according to the instruction manual of GATEWAYTM Cloning Technology (Invitrogen, Groningen, Netherlands). An ~1.6-kb DNA fragment was amplified by PCR using the Marathon ReadyTM cDNA derived from human bone marrow (Clontech) as a template, and two primers, 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAAAGGTGACGAGGAGCAGCTGGCAC-3' and 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCATGTTTTTTTGCTACTTGTCTTCTGT-3'. The amplified fragment was inserted into the vector pDONRTM 201 (Invitrogen), then transferred into the expression vector pFBIF to construct pFBIF-CSGalNAcT-2 as described previously (18). A CSGalNAcT-1 expression vector, pFBIF-CSGalNAcT-1, was also constructed as reported elsewhere (17). The catalytic domains of CSGalNAcT-1 and CSGalNAcT-2 were expressed in Sf21 insect cells. A 50-ml volume of culture medium was mixed and incubated with anti-FLAG M1 antibody resin (SIGMA). The resin was washed twice with 50 mM Tris-buffered saline (50 mM Tris-HCl, pH 7.4, and 150 mM NaCl) containing 1 mM CaCl2 and suspended in 100 µl of each assay buffer described below.

Construction of beta 4GalT-7, beta 3GalT-6, and GlcAT-I Fused with FLAG Peptides-- The putative catalytic domain of beta 4GalT-7, beta 3GalT-6, or GlcAT-I was expressed as secreted protein fused with FLAG peptide in insect cells or COS-1 cells as described in detail previously (17). Each enzyme was purified as described (17) and suspended in 100 µl of the glycosylation buffer described below.

Assay of CSGalNAcT Activity-- To determine the enzymatic activity, UDP-galactose (UDP-Gal) and UDP-N-acetylgalactosamine (UDP-GalNAc) (Sigma) were utilized as donor substrates. UDP-[3H]GalNAc (7.0 Ci/mmol) was purchased from PerkinElmer Life Sciences. For acceptor substrates, Gal-alpha -para-nitrophenyl (pNP), Gal-beta -pNP, GalNAc-alpha -benzyl, N-acetylglucosamine (GlcNAc)-alpha -pNP, GlcNAc-beta -pNP, glucose-alpha -pNP, glucose-beta -pNP, GlcA-beta -pNP, fucose-alpha -pNP, mannose-alpha -pNP, xylose (Xyl)-alpha -pNP, and Xyl-beta -pNP were obtained from Calbiochem (La Jolla, CA) and Sigma. Chondroitin and CS-A, -B, -C, and -D were purchased from Seikagaku Corporation (Tokyo, Japan). Chondroitin hexasaccharide and methoxyphenyl-linkage tetrasaccharides were kindly donated by Seikagaku Corporation. Oligosaccharides of CS and chondroitin were prepared as previously described (19).

For the GalT assay, 14 mM Hepes buffer (pH 7.4) containing 250 µM UDP-Gal, 12.5 mM MnCl2, and 500 µM of each acceptor substrate was used. For the GalNAcT assay, 50 mM MES buffer (pH 6.5) containing 0.1% Triton X-100, 1 mM UDP-GalNAc, 10 mM MnCl2, and 500 µM of each acceptor substrate was used. A 10-µl volume of enzyme solution for 20 µl of each reaction mixture was added and incubated at 37 °C for 2 h for the GalT and 16 h for the GalNAcT assay. After incubation, the mixture was filtrated with an Ultrafree-MC column (Millipore, Bedford, MA) and a 10-µl aliquot was subjected to reversed-phase high performance liquid chromatography on an ODS-80Ts QA column (4.6 × 250 mm; TOSOH, Tokyo, Japan). 0.1% Trifluoroacetic acid/H2O was used as a running solution and the products were eluted with a 0-15 (for GlcA-beta -pNP) or 7-10% (for linkage tetrasaccharide-para-methoxypheny) acetonitrile gradient at a flow rate of 1.0 ml/min at 50 °C. For glycosylated peptides, H2O containing 0.1% trifluoroacetic acid and 21% acetonitrile was utilized as the running solution. An ultraviolet spectrophotometer (absorbance at 210 nm), SPD-10AVP (Shimadzu, Kyoto, Japan) was used for detection of the peaks. In the analysis of glycosylated peptide, labeling was done with Cy5 (Amersham Biosciences) and fluorescence was detected with a fluorescence detector, RF-10AXL (Shimadzu). For the analysis of elongation activity, the CSGalNAcTs reaction mixture containing 100 µg of chondroitin or CS and 40,000-55,500 dpm of UDP-[14C]GalNAc was used. After a 1-h incubation at 37 °C, the reaction mixture was filtrated and fractionated with a G2500PW column (TOSOH, Tokyo, Japan) or Superdex 30 pg column (Amersham Biosciences). The radioactivity of each fraction was monitored by liquid scintillation spectrophotometry.

Assay of CSGalNAcT Activity with a Tetrasaccharide-bikunin Peptide-- A Xyl-bikunin peptide (VLPQEEEGS(-Xyl)GGGQLVT) was purchased from the Peptide Institute Inc. (Osaka, Japan). The Cy5 (Amersham Biosciences)-labeled Xyl-peptide was incubated with 5 µl of three glycosyltransferases, beta 4GalT-7, beta 3GalT-6, and GlcAT-I, and 1 mM donor substrates, UDP-Gal and UDP-GlcA, at 37 °°C for 16 h as described in detail previously (17). A 50 mM MES buffer (pH 6.5) containing 0.1% Triton X-100, 1 mM UDP-Gal, 1 mM UDP-GlcA, 10 mM MnCl2, and 500 µM Xyl-bikunin peptide was used for the reaction. The glycosyltransferases for the synthesis of the tetrasaccharide-bikunin peptide were inactivated by heating at 95 °C for 5 min. Then, the reaction mixture was filtrated with an Ultrafree-MC column (Millipore), and a 10-µl aliquot was incubated with 1 mM donor substrate, UDP-GalNAc, and each CSGalNAcT at 37 °C for 8 h for the assay of initiation activity of each CSGalNAcT. The reaction products of CSGalNAcTs were filtrated with an Ultrafree-MC column and a 10-µl aliquot was subjected to reversed-phase high performance liquid chromatography on an ODS-80Ts QA column as described above.

Determination of Products by CSGalNAcT-2 with Mass Spectrometry (MS)-- An additional peak detected by reversed-phase chromatography was isolated and analyzed by an electrospray ionization (ESI) or matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS (ESI-MS, esquire3000plus, and MALDI-TOF-MS, Reflex IV; Bruker Daltonics, Billerica, MA). Then, 25 pmol of product was dissolved in 5 µl of H2O, and 45 µl of 0.1% formic acid and 50 µl of methanol were added. The product solution was infused at a rate of 3 µl/min with a capillary voltage of 3 kV. The hypothetical product peaks obtained by ESI-MS were analyzed by ESI tandem mass spectrometry (ESI-MS/MS). These analyses were done in both positive-ion and negative-ion ESI modes. For MALDI-TOF MS analysis, 10 pmol of product was dried, dissolved in 1 µl of H2O, and applied.

In Vivo CS/HS Synthesis on a Syndecan-4/FGF-1 Chimera Protein-- For the expression in CHO-K1 cells, the full-length cDNAs of CSGalNAcT-1 and CSGalNAcT-2 were amplified by PCR with primers CSGalNAc-T1, 5'-CCCAAGCTTATGATGATGGTTCGCCGGGGGCT-3' and 5'-GCTCTAGATCATGTTTTTTTGCTACTTGTCTTCTGT-3', and CSGalNAc-T2, 5'-CCCAAGCTTATAAGAATGCCTAGAAGAGGACTGA-3' and 5'-GCTCTAGATCAACCAACAGCTTCACTGTTTGTC-3'. The amplified fragments were inserted into pcDNA3.1/hygromycin(+) (pcDNA3.1/Hygro, Invitrogen) after HindIII and XbaI digestion. The resulting plasmid, pcDNA3.1/HygroCSGalNAcT-1,-CSGalNAcT-2, and the pcDNA3.1/Hygro expression vector were transfected into CHO-K1 cells harboring pMEXneo-PG-FGF-1 that were expressing the syndecan-4/FGF-1 chimera protein (PG-FGF-1) using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. Medium conditioned by the CHO transfectant containing the secreted PG-FGF-1 protein with GAGs was collected. Fractionation of PG-FGF-1 using a DEAE-Sepharose column (Amersham Biosciences) and endoglycosidases: heparitinase (HSase), heparanase (HPase), and chondroitinase ABC (CSase) (Seikagaku Corp.) digestion and Western blotting with monoclonal antibody against FGF-1 (mAb1) (20) were performed as described previously (21). The PG-FGF-1 bands digested by glycosidases were quantified by densitometric scanning of the digitized image using NIH Image (version 1.60) software (National Institutes of Health, Bethesda, MD).

Quantitative Analysis of CSGalNAcT-1 and CSGalNAcT-2 Transcripts in Human Tissues by Real-time PCR-- For quantification of the two CSGalNAcT transcripts, we employed the real-time PCR method, as described in detail previously (18, 22, 23). Marathon ReadyTM cDNAs derived from various human tissues and cells were purchased from Clontech. Standard curves for the endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNAs, were generated by serial dilution of a pCR2.1 (Invitrogen) DNA containing the GAPDH cDNA. The primer sets and the probes for CSGalNAcT-1 and CSGalNAcT-2 were as follows. The forward primer for CSGalNAcT-1 was 5'-GACTTCATCAATATAGGTGGGTTTGAT-3', the reverse primer, 5'-GTCCGTACCACTATGAGGTTGCT-3', and the probe, 5'-ACCTTTATCGCAAGTATCT-3' with a minor groove binder (24). The forward primer for CSGalNAc-T2 was 5'-CTGACCATTGGTGGATTTGACAT-3', the reverse primer, 5'-AACCGGAGTCCGAATCACAA-3', and the probe, 5'-CATCTTTATCGAAAATACTTACATGG-3' with a minor groove binder. PCR products were continuously measured with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The relative amount of each CSGalNAcT transcript was normalized to the amount of GAPDH transcript in the same cDNA.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Determination of Nucleotide and Amino Acid Sequence of CSGalNAcT-2-- We determined a novel full-length cDNA sequence by the 5'-rapid amplification of cDNA ends method and registered it in the GenBankTM data base with accession number AB079252. The nucleotide sequence and the putative amino acid sequence are shown in Fig. 1. This cDNA sequence consisted of a 254-bp 5'-untranslated region, 1629-bp coding region, and 1791-bp 3'-untranslated region that contained a poly-A tail (Fig. 1). Although the original expressed sequence tag was obtained in a GenBankTM data base search with beta 1,4-glycosyltransferase motifs as query sequences, the full-length ORF sequence was identified as highly homologous to CSGalNAcT as previously reported by us (17). We designated this novel cDNA as CSGalNAcT-2, and renamed the previous CSGalNAcT, CSGalNAcT-1. An alignment of CSGalNAcT-1 and CSGalNAcT-2 is shown in Fig. 2. A hydropathy profile of the putative amino acid sequence based on Kyte and Doolittle hydrophobicity plots indicates that the ORF of CSGalNAcT-2 encodes a typical type II membrane protein, which is consistent with the topology of other glycosyltransferases, with a cytoplasmic tail of 14 amino acids, a transmembrane domain of 20 amino acids, and a large catalytic portion of 508 amino acids. CSGalNAcT-2 contains a DXD motif, which is conserved in many glycosyltransferases and functions as a key sequence for divalent cation binding, and a GWGGED motif, which is highly conserved among some of the beta 4GalT family.


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 1.   Nucleotide and amino acid sequences of CSGalNAcT-2. The predicted start and stop codons are underlined. The splicing junctions are indicated with arrowheads. A poly(A) signal is double underlined.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 2.   Multiple alignment of amino acid sequences of CSGalNAcT-2 and CSGalNAcT-1 by GENETYX. Introduced gaps are shown with hyphens. The putative transmembrane domains are underlined. The DXD motif and the beta 1,4-glycosyltransferase motif are boxed. Identical amino acids are shown with asterisks. Possible N-glycosylation sites are indicated by arrowheads.

A genome sequence identical to that of the CSGalNAcT-2 cDNA was found in a genome clone (GenBankTM AC011890), which is localized on chromosome 10. The genomic structure of the CSGalNAcT-2 gene was determined to be composed of at least 7 exons by comparison between the cDNA and genome sequences (Fig. 1). The exon/intron junctions of CSGalNAcT-2 were identical to those of CSGalNAcT-1 (data not shown).

Determination of CSGalNAcT-2 Activity in Elongation and Initiation of Chondroitin Poly- and Oligosaccharides-- The truncated soluble forms of CSGalNAcT-1 and CSGalNAcT-2 were expressed in insect cells and employed for all experiments. On Western blotting using anti-FLAG antibody, each enzyme was detected as a single band corresponding to the predicted size (Fig. 3B). An additional band appeared by Coomassie staining at ~50 kDa shared by all lanes (Fig. 3A), however, the protein recovered from mock transfectants showed no activity for any donors and acceptor substrates (data not shown). At first, we screened the transfer activity of CSGalNAcT-2 using nine donor substrates and multiple monosaccharide-pNP acceptors. In screening of donor and acceptor substrates, CSGalNAcT-2 transferred a GalNAc residue to GlcA-pNP, however, no activity was observed with other combinations of donor and acceptor substrates (data not shown). It was identified in a previous report that CSGalNAcT-1 is beta 4GalNAcT, which transfers GalNAc to GlcA for initiation and elongation in the synthesis of CS (17). So far, the linkage of GalNAc with GlcA has been identified only in CS. We considered that CSGalNAcT-2 was also a GalNAcT involved in the synthesis of CS, and performed further analysis using CS-related substrates as acceptors.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Determination of CS elongation and initiation activities of CSGalNAcT-2. CSGalNAcT-1 and -2 were purified with anti-FLAG M1 antibody resin and were applied to SDS-PAGE. The detection of proteins was performed with Coomassie staining (A) and Western blotting using anti-FLAG antibody (B). C, chondroitin was used as an acceptor substrate for CSGalNAcT-2. The purified reaction mixtures were applied to a G2500PW column with 0.2 M NaCl as a running buffer at a flow rate of 0.6 ml/min. The radioactivity of each fraction (340 µl each) was quantified by liquid scintillation spectrophotometry. The peak of the reaction product is indicated with an arrow. D, linkage tetrasaccharide-O-methoxyphenyl was used as an acceptor, and the product was analyzed by reversed-phase chromatography. Each peak of substrate (peak S) and reaction product (peak P) was isolated and subjected to MALDI-TOF-MS analysis (E and F).

Two kinds of GalNAc-GlcA linkages are known in CS, one in its polymer structure (3GalNAcbeta 1-4GlcAbeta 1-)n and the other between the polymer CS and the linkage tetrasaccharide (GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xyl). At first, chondroitin was utilized as an acceptor substrate to examine the elongation activity of CSGalNAcT-2. As shown in Fig. 3C, CSGalNAcT-2 apparently transferred GalNAc to chondroitin to produce an additional peak (indicated by an arrow in Fig. 3C) as a reaction product. This peak was isolated and identified to have GalNAc on its nonreducing terminus with chondroitinase ACII treatment (data not shown), the method used having been described in a previous study (17). Second, a linkage tetrasaccharide (GlcAbeta 1-3Galbeta 1-3Galbeta 1-4Xylbeta -O-methoxyphenyl) synthesized chemically was utilized as an acceptor substrate to identify the initiation activity of CSGalNAcT-2. As shown in Fig. 3D, the peak P appeared at a 30.3-min retention time in addition to the acceptor substrate peak (peak S) at 31.1 min. Peaks S and P were isolated by reversed-phase chromatography and their molecular weights were determined by MALDI-TOF MS. Peak S gave a molecular mass of 779.14 m/z, the same as that of the linkage tetrasaccharide with Na+ (Fig. 3E). Peak P gave two peaks of 982.28 and 998.25 m/z as shown in Fig. 3F. The molecular mass of 982.28 or 998.25 m/z was the same molecular weight as a GalNAc-added linkage tetrasaccharide-O-methoxyphenyl with Na+ or with K+, respectively. Moreover, the peak P was identified to have GalNAc at its nonreducing terminus with chondroitinase ACII treatment (data not shown). These results suggested that CSGalNAcT-2 has two GalNAcT activities, i.e. elongation of chondroitin and initiation of the CS synthesis by transferring GalNAc to the linkage tetrasaccharide.

Comparison of Acceptor Substrate Specificity between CSGalNAcT-1 and CSGalNAcT-2-- In view of these results, CSGalNAcT-2 was suggested to be GalNAcT involved in the synthesis of CS as well as CSGalNAcT-1. To distinguish the functions of the two CSGalNAcTs, we compared GalNAcT activity toward GlcA found at the nonreducing terminus of various kinds of chondroitin-related acceptor substrates. The amount of enzyme was estimated by Western blotting, and approximately equal amounts of enzyme were used for the GalNAcT reaction. The results are summarized in Table I. Regarding the elongation activity, CSGalNAcT-2 utilized chondroitin polysaccharide as an acceptor more than any other substrate examined, and showed higher levels of enzymatic activity than CSGalNAcT-1 toward all substrates except for the linkage tetrasaccharide (Table I). Furthermore, CSGalNAcT-2 showed remarkably strong activity, compared with CSGalNAcT-1, toward sulfated substrates such as CS poly- and oligosaccharides (Table I). CS-A and CS-B, both of which are sulfated at position C-4 of GalNAc, were better substrates for CSGalNAcT-2 than CS-C, which is sulfated at position C-6 of GalNAc and CS-D, which is sulfated at C-6 of GalNAc and C-2 of GlcA (Fig. 4). CSGalNAcT-2 exhibited much stronger activity toward the longer oligosaccharides, prepared from chondroitin and CS, than toward the shorter ones. These results strongly indicated that CSGalNAcT-2 is much more active in the elongation of chondroitin and CS than is CSGalNAcT-1.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of acceptor specificity between two CSGalNAcTs
Values represent averages ± S.D. of triplicate experiments.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Determination of chondroitin and CS polymer elongation activity of CSGalNAcT-2. Chondroitin (open circle), CS-A (closed circle), CS-B (open square), CS-C (closed square), and CS-D (open triangle) were used as acceptor substrates. The fractions containing the CSGalNAcT product are indicated by an arrow.

Regarding the initiation activity, CSGalNAcT-1 preferred the linkage tetrasaccharide as substrate and showed a much higher level of activity for the linkage tetrasaccharide than did CSGalNAcT-2. This indicated that CSGalNAcT-1 is the enzyme mainly responsible for the initiation of chondroitin and CS synthesis, not for elongation. To examine whether two GalNAcTs show a synergistic effect for initiation and elongation activities, two enzymes were mixed in the enzyme reaction toward the linkage tetrasaccharide or chondroitin. We observed additional effects of GalNAcT activity, but not synergistic effect, to any acceptor substrates (data not shown).

Comparison of Initiation Activity with Linkage Tetrasaccharide Peptide between Two CSGalNAcTs-- We performed an in vitro enzymatic synthesis of a chondroitin pentasaccharide-bikunin peptide (VLPQEEEGS*GGGQLVT; the peptide sequence encodes the NH2-terminal sequence of bikunin and the serine residue with an asterisk is attached with a saccharide chain) for determination of the initiation activity by CSGalNAcTs. Peak S in Fig. 5A, which was identified to possess the linkage tetrasaccharide (GlcA-Gal-Gal-Xyl-bikunin peptide) in a previous study, was used as the acceptor substrate. To obtain the relative activity of each enzyme, equal amounts of enzyme were employed, and the incubation was terminated before a large amount of acceptor substrate remained. As seen in Fig. 5, B and C, the reaction product (Peak P) appeared at 30.1 min with CSGalNAcT-1 or -2, respectively. Peak P was identified as GalNAc-GlcA-Gal-Gal-Xyl-bikunin peptide in a previous study (17). The peak area of the CSGalNAcT-1 product (Fig. 5C) was 3-fold larger than that of the CSGalNAcT-2 product (Fig. 5B). The value of this relative activity was consistent with that toward the methoxyphenyl-linkage tetrasaccharide in Table I, i.e. the activity of CSGalNAcT-1 was 2.3-fold that of CSGalNAcT-2. These results indicated that the presence of bikunin peptide does not influence the relative activity of the two CSGalNAcTs in vitro.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Comparison of initiation activity between two CSGalNAcTs. A, the GlcA-Gal-Gal-Xyl-bikunin peptide (peak S) was synthesized enzymatically with three glycosyltransferases, beta 4GalT-7, beta 3GalT-6, and GlcAT-I, and detected by a reversed-phase chromatography. The product (peak S) was used as an acceptor substrate for CSGalNAcT-2 (B) or CSGalNAcT-1 (C). The products (peak P) were identified as described previously (17).

Change of GAG Composition of PG-FGF-1 by CSGalNAcT-1 or CSGalNAcT-2 Transfection-- Previously, the gene construct encoding a chimera protein (PG-FGF-1) consisting of syndecan-4 and FGF-1 was transfected into CHO-K1 cells to express the chimera protein (21). Syndecan-4 is a well analyzed proteoglycan possessing chains of HS and/or CS. The GAG composition of PG-FGF-1 secreted from the stable transfectant cells with PG-FGF-1 had been analyzed. It was found that GAG on PG-FGF-1 consisted of large populations of HS and small populations of CS. The initiation of the synthesis of HS or CS is determined by alpha 4GlcNAcT or beta 4GalNAcT, respectively. If the two enzymes compete with the common linkage tetrasaccharide (GlcA-Gal-Gal-Xyl-Ser) as an acceptor in the cells, they would be key enzymes differentially regulating the number of HS or CS chains. To test this hypothesis, the CSGalNAcT-1 or CSGalNAcT-2 genes were introduced into CHO-K1 cells that were producing PG-FGF-1. The transcripts for CSGalNAcT-1 and CSGalNAcT-2 in the stable transfectant cells were quantified by real-time PCR. Their expression levels were almost 20 times higher than the physiological level in human placenta, in which the transcripts for the genes involved in the synthesis of CS are expressed at the highest level among many tissues (data not shown).

PG-FGF-1 secreted into the medium conditioned by the transfectants was detected by immunoblotting with anti-FGF-1 monoclonal antibody (mAb1) (20). PG-FGF-1 from CHO-K1 mock transfectants showed a major band with a large molecular mass of more than 200 kDa (Fig. 6, lane 1). The composition of GAGs on PG-FGF-1 was analyzed by glycosidase digestion. Digestion with chondroitinase ABC (CSase) yielded a protein band at 32 kDa (lane 2), which corresponds to the molecular mass of PG-FGF-1 with linkage saccharides, although most proteins remained at a large molecular mass. The ratio of CS to CS plus HS on PG-FGF-1 was obtained by measurement of the intensity of the 32-kDa band, for example, the ratio of CS/CS + HS on PG-FGF-1 produced by the mock transfectants was 9.5%, which was calculated as the intensity of the 32-kDa band in lane 2 divided by that in lane 4. This indicated that PG-FGF-1 containing only CS without HS occupied only 9.5% of total PG-FGF-1, and HS occupied most of the PG-FGF-1 produced by the mock-transfected CHO-K1 cells. Digestion of PG-FGF-1 (lane 3) with a mixture of heparitinase (HSase) and heparanase (HPase) yielded a strong 32-kDa band, however, faint smear bands, which probably carry CS, were detected at a molecular mass of approximately 40-70 kDa. CSase treatment of PG-FGF-1 recovered from the CSGalNAcT-2 transfectants did not change significantly the intensity of the 32-kDa band, compared with the control (9.5 in lane 2 versus 4.3% in lane 6). In contrast, CSase treatment of PG-FGF-1 recovered from the CSGalNAcT-1 transfectants apparently increased the intensity of the 32-kDa band (9.5 in lane 2 versus 39.1% in lane 10). The above results indicated that CSGalNAcT-1 effectively initiates the synthesis of CS and increases the number of CS chains by transferring GalNAc to the linkage tetrasaccharide on syndecan-4, but CSGalNAcT-2 did not exert initiation activity in the cells.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 6.   Change of GAG composition in Syndecan-4/FGF-1 (PG-FGF-1) secreted by CHO-K1 cells transfected with the CSGalNAcT-2 or CSGalNAcT-1 genes. PG-FGF-1 recovered from the culture medium of CHO-K1 cells transfected with the mock vector (lanes 1-4), the CSGalNAcT-2 gene (lanes 5-8), and the CSGalNAcT-1 gene (lanes 9-12) were resolved by SDS-PAGE and immunoblotted with mAb1. Aliquots of the sample were subjected to endoglycosidase digestion before being subjected to SDS-PAGE. PG-FGF-1 was left untreated (lanes 1, 5, and 9), or digested with CSase (lane 2, 6, and 10), with a mixture of HPase and HSase (lane 3, 7, and 11), or with a mixture of all enzymes (lane 4, 8, and 12). Positions of molecular mass standards are indicated in kilodaltons. The density of each band was measured with a film exposed for 2 min.

Tissue Distribution of CSGalNAcT-2 Transcripts-- We determined the tissue distribution and expression levels of CSGalNAcT-2 transcripts, in comparison with CSGalNAcT-1 transcripts, by the real-time PCR method. The expression levels of both genes in various human tissues were shown as the relative amount versus GAPDH transcripts (Fig. 7). Both genes were expressed ubiquitously in all tissues examined. However, the expression profiles differed from each other, i.e. CSGalNAcT-2 was highly expressed in the small intestine, leukocyte, and spleen, whereas CSGalNAcT-1 was highly expressed in the placenta and thyroid gland.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Quantitative analysis of CSGalNAcT-2 and CSGalNAcT-1 transcripts in human tissues by real-time PCR. Standard curves for CSGalNAcTs and GAPDH were generated by serial dilution of each plasmid DNA. The expression level of the CSGalNAcT-2 (open bars) and CSGalNAcT-1 (closed bars) transcripts was normalized to that of the GAPDH transcript, which was measured in the same cDNAs. Data were obtained from triplicate experiments and are given as the mean ± S.D. PBMC, peripheral blood mononuclear cell.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The investigation of CS has progressed to the relationship between its structural properties including saccharide composition and sulfation, and its biological function. However, the mechanisms of its biosynthesis, such as the number of enzymes participating and their roles, still remained to be elucidated. To date, three glycosyltransferases, CSS (14), CSGlcAT (15), and CSGalNAcT-1 (16, 17), which participate in the biosynthesis of CS, have been reported. In this study, a novel enzyme CSGalNAcT-2 was found to be a fourth member involved in the synthesis, and identified to be the second GalNAcT transferring a GalNAc to GlcA.

The amino acid sequence of CSGalNAcT-2 is highly homologous to that of CSGalNAcT-1. The beta 4GT motif (GWGGED) and DXD sequence, which is a divalent cation binding motif, are conserved with a good alignment (Fig 2). Six beta 4GalTs, beta 4GalT-1 to -6, possess a WGWGGEDDD sequence as the motif (25-28), whereas both of the CSGalNAcTs possess KGWGGEDVH in place of WGWGGEDDD. Very recently, Ramakrishnan et al. (29) reported that Tyr289 of bovine beta 4GalT-1 is essential for its donor binding based on its crystallized structure. The elimination of a hydrogen bond by mutating the Tyr289 residue to Leu, Ile, or Asn enhances the GalNAcT activity in place of the GalT activity. In the case of beta 4GalNAcT of Caenorhabditis elegans, the amino acid at the same position is Ile (47). In the primary sequence of CSGalNAcT-1 and -2, it was difficult to find the amino acid residue corresponding to the position of Tyr289 on beta 4GalT-1 because of a gap in the amino acid alignment between beta 4GalT-1 and CSGalNAcTs. However, CSGalNAcT-2 has an almost identical sequence to that of CSGalNAcT-1 around this region that probably determines the donor substrate specificity. Therefore, the beta 4GalNAcT activity of CSGalNAcT-2 was easily predicted before the experiments. In fact, CSGalNAcT-2, as well as CSGalNAcT-1, exhibited GalNAcT activity in both the initiation and elongation of the CS synthesis in vitro (Table I). However, CSGalNAcT-2 showed remarkably different activity from CSGalNAcT-1, i.e. much stronger activity toward chondroitin and CS substrates, particularly CS-A and CS-B, than CSGalNAcT-1 (Table I and Fig. 4). Sulfation of chondroitin is important to exhibit various biological functions. Sulfation at position C-4 of GalNAc is directed by chondroitin-4-O-sulfotransferase-1 (C4ST-1) (30), C4ST-2 (31), and C4ST-3 (32), that at C-6 of GalNAc by chondroitin-6-O-sulfotransferase-1 (C6ST-1) (33) and C6ST-2 (34), and that at C-2 of GlcA by uronyl 2-sulfotransferase (35) in the GalNAc-GlcA backbone. It is still unclear whether the sulfation occurs after the synthesis of the long chondroitin chain or the sulfation and GalNAc-GlcA polymerization occur simultaneously. The preference of CSGalNAcT-2 for sulfated substrates indicates that the elongation of sulfated chondroitin is directed by CSGalNAcT-2, not by CSGalNAcT-1. CSGalNAcT-2 may be responsible for the elongation of polymers that are simultaneously coupled with sulfation.

Regarding the initiation activity, CSGalNAcT-1 exhibited much stronger GalNAcT activity toward the linkage tetrasaccharide than CSGalNAcT-2. In a previous study, we reported that CSGalNAcT-1 has effective initiation activity, i.e. it transferred GalNAc to the linkage tetrasaccharide conjugated with a bikunin peptide (GlcA-Gal-Gal-Xyl-bikunin peptide) in vitro (17). The initiation activity of CSGalNAcT-1 relative to CSGalNAcT-2 was 2.3- and 3.0-fold higher toward methoxyphenyl-linkage tetrasaccharide and tetrasaccharide-bikunin peptide, respectively. The presence of a peptide backbone did not affect the relative initiation activity. The in vivo assay system using the syndecan-4/FGF-1 chimera protein (PG-FGF-1) demonstrated that CSGalNAcT-1 exhibits initiation activity for syndecan-4 by competing with the synthesis of HS (Fig. 6). Syndecan-4 is a complex-type PG that has four putative GAG attachment sites, and both CS and HS can bind to these sites (36). In our construction of PG-FGF-1, a part of syndecan-4 containing three GAG attachment sites was ligated to the NH2 terminus of FGF-1 (21). The intensity of the 32-kDa band after CSase or HSase/HPase treatment of PG-FGF-1 reflects the CS and HS composition of PG-FGF-1 as demonstrated in our previous study (21). In this assay system, we identified an increase in CS on PG-FGF-1 only in CSGalNAcT-1-transfected CHO-K1 cells, not in CSGalNAcT-2 transfectants. The increase of CS is probably directed by the initiation activity of CSGalNAcT-1. This in vivo observation is consistent with previous results in vitro of the effective initiation activity of CSGalNAcT-1 as we reported (17). Taken together with the previous findings in vitro, the in vivo results of the present study strongly support that CSGalNAcT-1 is the enzyme most responsible for the initiation of CS synthesis in the cells.

On the other hand, CSGalNAcT-2 transfected into CHO-K1 cells showed no increase in CS, although it had some initiation activity in vitro toward the linkage tetrasaccharide. This contradiction between the in vitro and in vivo activities of CSGalNAcT-2 suggests that the initiation of CS synthesis might be controlled by some unknown mechanisms. One possibility is the effect of sulfation on the linkage tetrasaccharide. In vertebrates, CS is specifically sulfated at position C-6 of the inner Gal (Galbeta 1-4) and at C-4 and C-6 of the outer Gal (Galbeta 1-3) in the linkage tetrasaccharide (37, 38). These sulfations might influence the CSGalNAcTs in terms of recognition. Another possibility is the effect of the peptide sequence of the core protein on the enzyme recognition. A currently proposed GAG attachment motif is the Ser-Gly-Ser-Gly sequence and surrounding acidic amino acids (39, 40). CSGalNAcT-2 might recognize CS binding peptide sequences of core proteins other than syndecan-4.

The tissue distribution of transcripts for three glycosyltransferase genes, i.e. CSS, CSGlcAT, and CSGalNAcT-1, have been reported to be ubiquitously expressed in all tissues examined (14-17). CSGalNAcT-2 also showed a ubiquitous expression like the others. However, characteristic of that CSGalNAcT-2 was a high level of expression in the small intestine, leukocytes, and spleen, whereas the others are not so highly expressed in these tissues. Hiraoka et al. (31) reported that the transcripts of C4ST-1 and C4ST-2, which produce CS-A, are also highly expressed in the small intestine, spleen, and leukocytes. In contrast, C6ST-2, which produces CS-C, is expressed significantly in the spleen, but not so in small intestine (34). The preference of CSGalNAcT-2 for CS-A and CS-B to CS-C and CS-D, as demonstrated in Table I, led us to speculate of a cooperative CS synthesis by CSGalNAcT-2 and C4STs in the cells. The similar profile of the tissue distribution of CSGalNAcT-2 to that of C4STs further suggested this cooperative synthesis. In the case of HS, it has been proposed that EXTL2 and EXTL3 are involved in the initiation of the synthesis (12, 13), however, the exact role of each enzyme in vivo remains to be elucidated.

Finally, the catalytic activities of each enzyme involved in the synthesis of HS and CS are schematically summarized in Fig. 8. Four glycosyltransferases responsible for the synthesis of the linkage tetrasaccharide have been cloned and analyzed (41-46). Using these enzymes, it is now possible to synthesize enzymatically the linkage tetrasaccharide bound to the peptide (17). The initiation of the CS chain is also feasible using CSGalNAcT-1 (17). Three enzymes, i.e. CSS, CSGlcAT, and CSGalNAcT-2, have been identified as involved in the polymerization of the CS chain. In addition to the four enzymes, there still may be unknown enzymes, which remain to be cloned and analyzed, for the synthesis of CS.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   A schematic diagram of catalytic activities of glycosyltransferases involved in the synthesis of HS and CS. The scale of the letters of enzyme names indicates the strength of activity. Xylosyltransferase (XT) (41, 42), beta 1,4-galactosyltransferase VII (beta 4GalT7) (43, 44), beta 1,3-galactosyltransferase VI (beta 3GalT6) (45), and beta 1,3-glucuronyltransferase I (GlcAT-I) (46) work sequentially for the synthesis of linkage tetrasaccharide. In the case of HS/HP synthesis, EXT1 and EXT2, which are HS polymerases having both beta 1,4-glucuronyltransferase and alpha 1,4-N-acetylglucosaminyltransferase activities (11), and EXTL1, EXTL2, and EXTL3, which are HS alpha 1,4-N-acetylglucosaminyltransferases (12, 13), participate. In the case of CS/DS synthesis, CSS, which is CS synthase having both beta 1,4-glucuronyltransferase and beta 1,4-N-acetylgalactosaminyltransferase activities (14), and CS beta 1,3-glucuronyltransferase (CSGlcA-T) (15) and CS beta 1,4-N-acetylgalactosaminyltransferase 1 and 2 (CSGalNAcT-1 and CSGalNAcT-2) (Ref. 17 and this paper) participate.


    ACKNOWLEDGEMENT

We thank Seikagaku Corporation for providing an acceptor substrate of the linkage tetrasaccharide, GlcA-Gal-GalXyl-O-methoxyphenyl.

    FOOTNOTES

* This work was performed as part of the R&D Project of Industrial Science and Technology Frontier Program (R&D for Establishment and Utilization of a Technical Infrastructure for Japanese Industry) supported by the New Energy and Industrial Technology Development Organization (NEDO).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AB079252.

¶¶ To whom correspondence should be addressed: Glycogene Function Team, Research Center for Glycoscience (RCG), National Institute of Advanced Industrial Science and Technology (AIST), Central-2 C-2, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan. Tel.: 81-298-61-3200; Fax: 81-298-61-3201; E-mail: h.narimatsu@aist.go.jp.

Published, JBC Papers in Press, November 20, 2002, DOI 10.1074/jbc.M208886200

    ABBREVIATIONS

The abbreviations used are: PG, proteoglycan; GAG, glycosaminoglycan; CS, chondroitin sulfate; HS, heparan sulfate; FGF, fibroblast growth factor; GlcA, glucuronic acid; Gal, galactose; Xyl, xylose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; GT, glycosyltransferase; (beta 4, beta 3, or CS)GlcAT, (beta 1,4-, beta 1,3- or CS)glucuronyltransferase; alpha 4GlcNAcT, alpha 1,4-N-acetylglucosaminyltransferase; (beta 4 or CS)GalNAcT, (beta 1,4- or CS)N-acetylgalactosaminyltransferase; (beta 4)GalT, (beta 1,4-)galactosyltransferase; CSS, chondroitin synthase; ORF, open reading frame; UDP, uridine diphosphate; pNP, para-nitrophenyl; MES, 2-morpholinoethanesulfonic acid; ESI, electrospray ionization; MS, mass spectrometry; MALDI-TOF, matrix-assisted laser desorption ionization-time of flight; HSase, heparitinase; HPase, heparanase; CSase, chondroitinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CHO, Chinese hamster ovary; mAb, monoclonal antibody; C4ST, chondroitin-4-O-sulfotransferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Perrimon, N., and Bernfield, M. (2000) Nature 404, 725-728[CrossRef][Medline] [Order article via Infotrieve]
2. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. (1992) Mol. Cell. Biol. 12, 240-247[Abstract]
3. Ashikari, S., Habuchi, H., and Kimata, K. (1995) J. Biol. Chem. 270, 29586-29593[Abstract/Free Full Text]
4. Tanaka, Y., Kimata, K., Adams, D. H., and Eto, S. (1998) Proc. Assoc. Am. Phys. 110, 118-125[Medline] [Order article via Infotrieve]
5. Oohira, A., Matsui, F., Tokita, Y., Yamauchi, S., and Aono, S. (2000) Arch. Biochem. Biophys. 374, 24-34[CrossRef][Medline] [Order article via Infotrieve]
6. Kawashima, H., Hirose, M., Hirose, J., Nagakubo, D., Plaas, A. H., and Miyasaka, M. (2000) J. Biol. Chem. 275, 35448-35456[Abstract/Free Full Text]
7. Zou, K., Muramatsu, H., Ikematsu, S., Sakuma, S., Salama, R. H., Shinomura, T., Kimata, K., and Muramatsu, T. (2000) Eur. J. Biochem. 267, 4046-4053[Abstract/Free Full Text]
8. Plaas, A. H., Wong-Palms, S., Roughley, P. J., Midura, R. J., and Hascall, V. C. (1997) J. Biol. Chem. 272, 20603-20610[Abstract/Free Full Text]
9. Bayliss, M. T., Osborne, D., Woodhouse, S., and Davidson, C. (1999) J. Biol. Chem. 274, 15892-15900[Abstract/Free Full Text]
10. Sugahara, K., and Yamada, S. (2000) Trends Glycosci. Glycotech. 12, 321-349
11. Senay, C., Lind, T., Muguruma, K., Tone, Y., Kitagawa, H., Sugahara, K., Lidholt, K., Lindahl, U., and Kusche-Gullberg, M. (2000) EMBO Rep. 1, 282-286[Abstract/Free Full Text]
12. Kitagawa, H., Shimakawa, H., and Sugahara, K. (1999) J. Biol. Chem. 274, 13933-13937[Abstract/Free Full Text]
13. Kim, B. T., Kitagawa, H., Tamura, J., Saito, T., Kusche-Gullberg, M., Lindahl, U., and Sugahara, K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7176-7181[Abstract/Free Full Text]
14. Kitagawa, H., Uyama, T., and Sugahara, K. (2001) J. Biol. Chem. 276, 38721-38726[Abstract/Free Full Text]
15. Gotoh, M., Yada, T., Sato, T., Akashima, T., Iwasaki, H., Mochizuki, H., Inaba, N., Togayachi, A., Kudo, T., Watanabe, H., Kimata, K., and Narimatsu, H. (2002) J. Biol. Chem. 277, 38179-38188[Abstract/Free Full Text]
16. Uyama, T., Kitagawa, H., Tamura Ji, J., and Sugahara, K. (2002) J. Biol. Chem. 277, 8841-8846[Abstract/Free Full Text]
17. Gotoh, M., Sato, T., Akashima, T., Iwasaki, H., Kameyama, A., Mochizuki, H., Yada, T., Inaba, N., Zhang, Y., Kikuchi, N., Kwon, Y., Togayachi, A., Kudo, T., Nishihara, S., Watanabe, H., Kimata, K., and Narimatsu, H. (2002) J. Biol. Chem. 277, 38189-38196[Abstract/Free Full Text]
18. Iwai, T., Inaba, N., Naundorf, A., Zhang, Y., Gotoh, M., Iwasaki, H., Kudo, T., Togayachi, A., Ishizuka, Y., Nakanishi, H., and Narimatsu, H. (2002) J. Biol. Chem. 277, 12802-12809[Abstract/Free Full Text]
19. Gundlach, M. W., and Conrad, H. E. (1985) Biochem. J. 226, 705-714[Medline] [Order article via Infotrieve]
20. Imamura, T., Oka, S., Tanahashi, T., and Okita, Y. (1994) Exp. Cell Res. 215, 363-372[CrossRef][Medline] [Order article via Infotrieve]
21. Yoneda, A., Asada, M., Oda, Y., Suzuki, M., and Imamura, T. (2000) Nat. Biotechnol. 18, 641-644[CrossRef][Medline] [Order article via Infotrieve]
22. Gibson, U. E., Heid, C. A., and Williams, P. M. (1996) Genome Res. 6, 995-1001[Abstract]
23. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996) Genome Res. 6, 986-994[Abstract]
24. Kutyavin, I. V., Afonina, I. A., Mills, A., Gorn, V. V., Lukhtanov, E. A., Belousov, E. S., Singer, M. J., Walburger, D. K., Lokhov, S. G., Gall, A. A., Dempcy, R., Reed, M. W., Meyer, R. B., and Hedgpeth, J. (2000) Nucleic Acids Res. 28, 655-661[Abstract/Free Full Text]
25. Almeida, R., Amado, M., David, L., Levery, S. B., Holmes, E. H., Merkx, G., van Kessel, A. G., Rygaard, E., Hassan, H., Bennett, E., and Clausen, H. (1997) J. Biol. Chem. 272, 31979-31991[Abstract/Free Full Text]
26. Schwientek, T., Almeida, R., Levery, S. B., Holmes, E. H., Bennett, E., and Clausen, H. (1998) J. Biol. Chem. 273, 29331-29340[Abstract/Free Full Text]
27. Lo, N. W., Shaper, J. H., Pevsner, J., and Shaper, N. L. (1998) Glycobiology 8, 517-526[Abstract/Free Full Text]
28. Amado, M., Almeida, R., Schwientek, T., and Clausen, H. (1999) Biochim. Biophys. Acta 1473, 35-53[Medline] [Order article via Infotrieve]
29. Ramakrishnan, B., and Qasba, P. K. (2002) J. Biol. Chem. 277, 20833-20839[Abstract/Free Full Text]
30. Yamauchi, S., Mita, S., Matsubara, T., Fukuta, M., Habuchi, H., Kimata, K., and Habuchi, O. (2000) J. Biol. Chem. 275, 8975-8981[Abstract/Free Full Text]
31. Hiraoka, N., Nakagawa, H., Ong, E., Akama, T. O., Fukuda, M. N., and Fukuda, M. (2000) J. Biol. Chem. 275, 20188-20196[Abstract/Free Full Text]
32. Kang, H. G., Evers, M. R., Xia, G., Baenziger, J. U., and Schachner, M. (2002) J. Biol. Chem. 277, 34766-34772[Abstract/Free Full Text]
33. Fukuta, M., Kobayashi, Y., Uchimura, K., Kimata, K., and Habuchi, O. (1998) Biochim. Biophys. Acta 1399, 57-61[Medline] [Order article via Infotrieve]
34. Kitagawa, H., Fujita, M., Ito, N., and Sugahara, K. (2000) J. Biol. Chem. 275, 21075-21080[Abstract/Free Full Text]
35. Kobayashi, M., Sugumaran, G., Liu, J., Shworak, N. W., Silbert, J. E., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 10474-10480[Abstract/Free Full Text]
36. Shworak, N. W., Shirakawa, M., Mulligan, R. C., and Rosenberg, R. D. (1994) J. Biol. Chem. 269, 21204-21214[Abstract/Free Full Text]
37. Sugahara, K., Yamashina, I., De, Waard, P., Van Halbeek, H., and Vliegenthart, J. F. (1988) J. Biol. Chem. 263, 10168-10174[Abstract/Free Full Text]
38. Sugahara, K., Ohi, Y., Harada, T., de Waard, P., and Vliegenthart, J. F. (1992) J. Biol. Chem. 267, 6027-6035[Abstract/Free Full Text]
39. Esko, J. D., and Zhang, L. (1996) Curr. Opin. Struct. Biol. 6, 663-670[CrossRef][Medline] [Order article via Infotrieve]
40. Brinkmann, T., Weilke, C., and Kleesiek, K. (1997) J. Biol. Chem. 272, 11171-11175[Abstract/Free Full Text]
41. Gotting, C., Kuhn, J., Zahn, R., Brinkmann, T., and Kleesiek, K. (2000) J. Mol. Biol. 304, 517-528[CrossRef][Medline] [Order article via Infotrieve]
42. Kuhn, J., Gotting, C., Schnolzer, M., Kempf, T., Brinkmann, T., and Kleesiek, K. (2001) J. Biol. Chem. 276, 4940-4947[Abstract/Free Full Text]
43. Almeida, R., Levery, S. B., Mandel, U., Kresse, H., Schwientek, T., Bennett, E. P., and Clausen, H. (1999) J. Biol. Chem. 274, 26165-26171[Abstract/Free Full Text]
44. Okajima, T., Yoshida, K., Kondo, T., and Furukawa, K. (1999) J. Biol. Chem. 274, 22915-22918[Abstract/Free Full Text]
45. Bai, X., Zhou, D., Brown, J. R., Crawford, B. E., Hennet, T., and Esko, J. D. (2001) J. Biol. Chem. 276, 48189-48195[Abstract/Free Full Text]
46. Kitagawa, H., Tone, Y., Tamura, J., Neumann, K. W., Ogawa, T., Oka, S., Kawasaki, T., and Sugahara, K. (1998) J. Biol. Chem. 273, 6615-6618[Abstract/Free Full Text]
47. Kawar, Z. S., Van Die, I., and Cummings, R. D. (2002) J. Biol. Chem. 277, 34924-34932[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.